Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage Morphine is used for the management of chronic, moderate to severe pain.[A176050] Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.[L5728]
Marketing Status approved; investigational
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
UNII 76I7G6D29C
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tooth discolouration07.09.02.001--
Tooth disorder07.09.05.001--Not Available
Tooth loss12.01.17.026; 07.09.09.0010.000167%Not Available
Tremor17.01.06.002--
Trismus17.01.03.004; 15.05.04.004--
Type I hypersensitivity10.01.03.0060.000223%Not Available
Ulcer08.03.06.001--Not Available
Unresponsive to stimuli17.02.05.0310.004890%Not Available
Urethral disorder20.07.01.002--Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.0110.002863%
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Urine abnormality20.02.01.0130.000167%Not Available
Urticaria23.04.02.001; 10.01.06.0010.035955%
Vascular pain24.03.02.0260.000379%Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vasculitis necrotising24.12.04.029; 10.02.02.0080.000111%Not Available
Vasodilatation23.06.05.006; 24.03.02.003--Not Available
Vein discolouration24.03.02.004--Not Available
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vertigo positional17.02.12.004; 04.04.01.0050.000111%Not Available
Vision blurred17.17.01.010; 06.02.06.007--
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene